secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0000012208-23-000068
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q3 net sales down 7.1% YoY to $632.1M; lowers full-year 2023 outlook
----------------------------------------------------------------------------

- Net sales $632.1M, down 7.1% YoY; currency-neutral decline 7.9%; COVID sales dropped to $0.3M from $17.2M.
- Life Science segment sales $263.5M, down 17.1% YoY (currency-neutral -17.8%); diagnostics segment up 1.7%.
- Net income $106.3M ($3.64 diluted EPS) vs net loss of $162.8M ($5.48 loss) in prior year, driven by Sartorius fair value changes.
- Operating income $90.9M vs $94.6M; gross margin 53.1% vs 54.7%.
- CEO cites further deterioration in biopharma/biotech spending and China challenges; full-year FY2023 outlook lowered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/0000012208-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/bio-20231026.htm
  HTML page:      https://secwatch.observer/filing/0000012208-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer